You are here
Olafsson to leave Hikma Pharmaceuticals
May 24,2022 - Last updated at May 24,2022
Hikma Pharmaceuticals PLC. (Hikma) said on Tuesday that Siggi Olafsson has resigned from his position as chief executive officer (CEO), and from Hikma’s board of directors, to pursue other opportunities.
Said Darwazah, Hikma’s executive chairman and former CEO, will assume all CEO responsibilities, enabling Hikma to continue with its strategy while Siggi will remain available until he departs on June 24.
Darwazah will continue to work closely with the executive committee, including Hikma’s three divisional presidents, benefiting from their experience and strong management teams.
Thanking Olafsson, Darwazah said: “On behalf of Hikma’s board and the entire Group, I would like to thank Siggi for his leadership over the past four years.
Together with the executive committee, he has worked tirelessly to drive strategic momentum across all three businesses, especially during the challenging days of the pandemic. Hikma is on a strong footing and well positioned for future growth, and we wish Siggi well for the future”.
Related Articles
Hikma Pharmaceuticals PLC. (Hikma) and a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd.
AMMAN — Hikma Pharmaceuticals PLC (Hikma, Group), announced that Riad Mishlawi, president of the Group’s Injectables business, has been appo
Hikma Pharmaceuticals PLC.